About Scancell

Scancell develops active immunotherapies that harness the immune system against cancer. Using its Immunobody and Moditope platforms, the company creates off the shelf treatments that stimulate long lasting, tumour specific immunity in hard to treat cancers like advanced melanoma and solid tumours, offering patients alternatives where conventional treatments show limited effectiveness. The lead product, iSCIB1+, has shown encouraging results in advanced melanoma, activating strong immune responses with favourable safety. By creating patient accessible therapies that work with checkpoint inhibitors, Scancell addresses critical unmet needs in oncology, translating rigorous science into treatments that extend survival.